Drug Search Results
More Filters [+]

Eltrombopag

Alternative Names: eltrombopag, revolade, promacta, sb497115, sb-497115-gr
Latest Update: 2024-06-14
Latest Update Note: Clinical Trial Update

Product Description

Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells. The drug acts via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway to activate megakaryocyte proliferation and differentiation in bone marrow progenitor cells, similar to those observed with endogenous thrombopoietin.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19368418/)

Mechanisms of Action: TPO Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Hepatitis | Hepatitis, Chronic | Anemia | Anemia, Aplastic | Thrombocytopenia | Purpura, Thrombocytopenic, Idiopathic | Hepatitis C | Hepatitis C, Chronic | Injuries/wounds Unspecified

Known Adverse Events: Headache | Anemia | Diarrhea

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eltrombopag

Countries in Clinic: Austria, Brazil, Chile, China, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Mexico, Oman, Portugal, Russia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States

Active Clinical Trial Count: 21

Highest Development Phases

Phase 3: Anemia, Aplastic|Pancytopenia

Phase 2: Acute Myeloid Leukemia|Anemia, Refractory|Chronic Lymphoid Leukemia|Communicable Diseases|Graft vs Host Disease|Lymphocytic Chronic B-Cell Leukemia|Lymphoma|Myelodysplastic Syndrome|Preleukemia|Purpura, Thrombocytopenic, Idiopathic|Stem Cell Transplant|Thrombocytopenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CETB115L11201

P2

Recruiting

Preleukemia|Myelodysplastic Syndrome

2026-01-15

24%

2015-003166-91

P2

Unknown status

Anemia, Aplastic|Anemia, Refractory

2025-11-22

EPBSCH

P2

Recruiting

Stem Cell Transplant|Lymphoma

2025-03-31

jRCT2021210004

P2

Recruiting

Myelodysplastic Syndrome

2025-03-31

Recent News Events